Liquidia (LQDA) | Financial Analysis & Statements
Liquidia Corporation Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
92.0M
Gross Profit
85.0M
92.33%
Operating Income
19.8M
21.50%
Net Income
14.6M
15.82%
Balance Sheet Metrics
Total Assets
327.9M
Total Liabilities
283.2M
Shareholders Equity
44.7M
Debt to Equity
6.33
Cash Flow Metrics
Operating Cash Flow
7.6M
Free Cash Flow
40.2M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Liquidia Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 158.3M | 14.0M | 17.5M | 15.9M | 12.9M |
| Cost of Goods Sold | 13.2M | 5.9M | 2.9M | 2.9M | 3.0M |
| Gross Profit | 145.1M | 8.1M | 14.6M | 13.1M | 9.8M |
| Gross Margin % | 91.6% | 58.0% | 83.5% | 82.1% | 76.5% |
| Operating Expenses | |||||
| Research & Development | 39.3M | 47.8M | 43.2M | 19.4M | 20.5M |
| Selling, General & Administrative | 157.2M | 81.6M | 44.7M | 32.4M | 23.1M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 196.5M | 129.4M | 88.0M | 51.8M | 43.6M |
| Operating Income | -51.4M | -121.3M | -73.4M | -38.8M | -33.8M |
| Operating Margin % | -32.5% | -866.6% | -419.6% | -243.3% | -263.0% |
| Non-Operating Items | |||||
| Interest Income | 6.6M | 7.7M | 3.5M | 1.1M | 33.0K |
| Interest Expense | 24.2M | 12.5M | 6.3M | 2.3M | 762.0K |
| Other Non-Operating Income | - | -4.3M | -2.3M | -997.0K | -53.0K |
| Pre-tax Income | -68.9M | -130.4M | -78.5M | -41.0M | -34.6M |
| Income Tax | - | - | - | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -68.9M | -130.4M | -78.5M | -41.0M | -34.6M |
| Net Margin % | -43.5% | -931.7% | -448.9% | -257.4% | -269.0% |
| Key Metrics | |||||
| EBITDA | -43.2M | -111.4M | -67.7M | -34.0M | -28.2M |
| EPS (Basic) | - | $-1.66 | $-1.21 | $-0.67 | $-0.70 |
| EPS (Diluted) | - | $-1.66 | $-1.21 | $-0.67 | $-0.70 |
| Basic Shares Outstanding | - | 78707503 | 64993476 | 60958862 | 49677737 |
| Diluted Shares Outstanding | - | 78707503 | 64993476 | 60958862 | 49677737 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Liquidia Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 190.7M | 176.5M | 83.7M | 93.3M | 57.5M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 54.1M | 2.7M | 4.1M | 5.0M | 3.0M |
| Inventory | 23.8M | 241.0K | - | - | - |
| Other Current Assets | 4.8M | 5.7M | 2.2M | 1.5M | 792.0K |
| Total Current Assets | 273.4M | 185.1M | 89.9M | 99.8M | 61.3M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 9.2M | 11.1M | 8.5M | 8.4M | 9.0M |
| Goodwill | 10.8M | 11.0M | 11.2M | 11.5M | 12.2M |
| Intangible Assets | 3.0M | 3.2M | 3.4M | 3.7M | 4.4M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 31.9M | 25.7M | 14.9M | 15.5M | 16.7M |
| Total Non-Current Assets | 54.5M | 45.2M | 28.4M | 29.4M | 32.5M |
| Total Assets | 327.9M | 230.3M | 118.3M | 129.2M | 93.7M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 3.7M | 4.7M | 1.4M | 2.2M | 1.1M |
| Short-term Debt | 58.9M | 18.4M | 1.1M | 1.1M | 1.1M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 135.8M | 41.8M | 18.6M | 8.8M | 7.3M |
| Non-Current Liabilities | |||||
| Long-term Debt | 139.0M | 104.0M | 2.4M | 23.4M | 15.0M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 147.4M | 111.3M | 52.5M | 30.0M | 21.1M |
| Total Liabilities | 283.2M | 153.0M | 71.0M | 38.8M | 28.5M |
| Equity | |||||
| Common Stock | 87.0K | 85.0K | 69.0K | 64.0K | 52.0K |
| Retained Earnings | -626.3M | -559.5M | -429.1M | -350.6M | -309.6M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 44.7M | 77.3M | 47.3M | 90.4M | 65.3M |
| Key Metrics | |||||
| Total Debt | 197.9M | 122.4M | 3.5M | 24.5M | 16.1M |
| Working Capital | 137.6M | 143.3M | 71.3M | 91.0M | 53.9M |
Balance Sheet Composition
Liquidia Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -68.9M | -130.4M | -78.5M | -41.0M | -34.6M |
| Depreciation & Amortization | 1.5M | 2.2M | 2.2M | 3.6M | 5.6M |
| Stock-Based Compensation | 29.5M | 18.8M | 10.1M | 9.3M | 6.7M |
| Working Capital Changes | -79.6M | -8.2M | -1.1M | -2.0M | -13.0M |
| Operating Cash Flow | -91.1M | -101.1M | -50.8M | -29.4M | -34.8M |
| Investing Activities | |||||
| Capital Expenditures | -4.3M | -4.9M | -1.3M | -587.0K | -107.0K |
| Acquisitions | - | - | - | - | 0 |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -4.3M | -4.9M | -1.3M | -587.0K | -107.0K |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 75.0M | 57.5M | 41.7M | 19.8M | 10.4M |
| Debt Repayment | -21.2M | -5.0M | -22.4M | -10.8M | -10.8M |
| Financing Cash Flow | 54.9M | 191.6M | 42.1M | 63.9M | 26.3M |
| Free Cash Flow | -42.0M | -101.9M | -52.9M | -29.2M | -34.1M |
| Net Change in Cash | -40.5M | 85.6M | -10.0M | 33.9M | -8.6M |
Cash Flow Trend
Liquidia Key Financial Ratios
Valuation Ratios
Forward P/E
7.08
Price to Book
72.24
Price to Sales
20.63
PEG Ratio
7.08
Profitability Ratios
Profit Margin
-43.54%
Operating Margin
21.50%
Return on Equity
-111.06%
Return on Assets
-11.50%
Financial Health
Current Ratio
2.01
Debt to Equity
442.32
Beta
0.46
Per Share Data
EPS (TTM)
$-0.80
Book Value per Share
$0.51
Revenue per Share
$1.84
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| LQDA | 3.3B | - | 72.24 | -111.06% | -43.54% | 442.32 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Axsome Therapeutics | 9.5B | -50.54 | 105.31 | -252.12% | -28.69% | 247.03 |
| Praxis Precision | 9.6B | - | 9.46 | -45.83% | 0.00% | 0.01 |
| Bio-Techne | 9.1B | 117.16 | 4.55 | 3.80% | 6.41% | 20.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.






